Delving into the Latest Updates on Cannaxan GmbH with Synapse

概览

关联

2

项与 Cannaxan GmbH 相关的药物

Adezunap

靶点-

作用机制-

在研机构

Apurano Pharmaceuticals GmbH

原研机构

Cannaxan GmbH

在研适应症

创伤性脑损伤 [+11]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

AP-701

靶点-

作用机制-

在研机构-

原研机构

Cannaxan GmbH

在研适应症-

非在研适应症-

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

7

项与 Cannaxan GmbH 相关的临床试验

CTIS2022-500899-66-00 / Recruiting

Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis - DISCOVER_(ZNP)

开始日期2023-12-19

申办/合作机构

Cannaxan GmbH

[+1]

CTIS2022-500897-32-00 / Recruiting

Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy - DISCOVER_(PNP1)

开始日期2023-11-30

申办/合作机构

Cannaxan GmbH

[+1]

CTIS2022-500898-13-00 / Recruiting

Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy - DISCOVER_(PNP2)

开始日期2023-11-14

申办/合作机构

Cannaxan GmbH

[+1]

100 项与 Cannaxan GmbH 相关的临床结果

登录后查看更多信息

0 项与 Cannaxan GmbH 相关的专利（医药）

登录后查看更多信息

1

项与 Cannaxan GmbH 相关的文献（医药）

Medical Cannabis and Cannabinoids

A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery

Article

作者: Gottwald, Franz ; Lorenzl, Stefan ; Nistler, Angelika ; Haber, Georg ; Weck, Christiane ; Trummer, Carina ; Bremm, Christian ; Brand, Werner ; Grötsch, Renate ; Brehm, Laura

Introduction: A phase I, open-label clinical trial in healthy male subjects was conducted to assess the pharmacokinetic and safety profile of an oromucosal cannabinoid spray (AP701) containing a lipid-based nanoparticular drug formulation standardized to ∆-9-tetrahydrocannabinol (THC). Methods: Twelve healthy male subjects received a single dose of AP701 (12 sprays) containing 3.96 mg THC. Plasma samples were drawn 10 min–30 h post dose for analysis of THC and the active metabolite 11-hydroxy-∆-9-THC (11-OH-THC). Results: The single dose of the applied oromucosal cannabinoid spray AP701 (12 sprays, 3.96 mg THC) resulted in a mean maximum plasma concentration (Cmax) of 2.23 ng/mL (90% CI 1.22–3.24) and a mean overall exposure (area under the concentration-time curve from time 0 to last measurable concentration [AUC0–t]) of 7.74 h × ng/mL (90% CI 5.03–10.45) for THC. For the active metabolite 11-OH-THC, a Cmax of 2.09 mg/mL (90% CI 1.50–2.68) and AUC0–t of 10.4 h × ng/mL (90% CI 7.03–13.77) was found. The oromucosal cannabinoid spray AP701 caused only minor psychotropic effects despite the relatively high dosage applied by healthy subjects. No serious adverse effects occurred. Overall, the oromucosal cannabinoid spray AP701 was well tolerated. Conclusion: Compared to currently available drugs on the market, higher AUC values could be detected for the oromucosal cannabinoid spray AP701 despite administration of a lower dose. These comparatively higher blood levels caused only minor psychotropic adverse effects. The oromucosal cannabinoid spray AP701 was well tolerated at a single dose of 3.96 mg THC. The oromucosal administration may provide an easily applicable and titratable drug formulation with a high safety and tolerability profile.

100 项与 Cannaxan GmbH 相关的药物交易

登录后查看更多信息

100 项与 Cannaxan GmbH 相关的转化医学

登录后查看更多信息